使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to GE HealthCare's Third Quarter 2023 Earnings Conference Call. (Operator Instructions). As a reminder, this call is being recorded.
各位好,歡迎參加 GE HealthCare 2023 年第三季財報電話會議。(接線員指示)。提醒各位,本次電話會議將被錄音。
I would now like to turn the call over to Carolynne Borders, Head of Investor Relations. You may begin.
現在我想把電話交給投資人關係主管 Carolynne Borders。您可以開始了。
Carolynne Borders - Chief IR Officer
Carolynne Borders - Chief IR Officer
Thanks, operator. Welcome to GE HealthCare's Third Quarter 2023 Earnings Call. I'm joined by our President and CEO, Peter Arduini, and our Vice President and CFO, Jay Saccaro.
謝謝,接線員。歡迎參加 GE HealthCare 2023 年第三季財報電話會議。我與我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Jay Saccaro 一同出席。
Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today.
我們在電話會議中的發言將同時包含 GAAP 與非 GAAP 財務結果。GAAP 與非 GAAP 指標之間的調節表可在今日新聞稿以及我們網站上的簡報投影片中找到。在本次電話會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們對當前情況的看法。
As described in our SEC filings, actual results may differ materially due to risks and uncertainties. And with that, I'll hand the call over to Peter.
如我們向 SEC 提交的文件所述,實際結果可能因風險與不確定性而出現重大差異。接下來,我把電話交給 Peter。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Thanks, Carolynne. Good morning, everyone, and thanks for joining us today for our third quarter call. To start, I want to say we're pleased with our growth, margin and cash flow performance in the quarter. Recently, we've launched several new products, which I'll talk about in greater detail later and announced multiple strategic artificial intelligence-based collaborations aimed at supporting new product introductions and clinical applications.
謝謝你,Carolynne。各位早安,感謝今天加入我們的第三季電話會議。首先,我想說我們對本季的成長、利潤率與現金流表現感到滿意。近期我們推出了數項新產品,我稍後會更詳細說明;同時也宣布多項以策略性人工智慧為基礎的合作,旨在支援新產品導入與臨床應用。
We're honored to have received a grant from the Bill & Melinda Gates Foundation to develop ultrasound tools for less experienced health care professionals and support more effective obstetric and lung ultrasound screening, for patients in low and middle-income countries.
我們很榮幸獲得比爾與梅琳達・蓋茲基金會的補助,用於開發適合經驗較少的醫療專業人員使用的超音波工具,並支援在低與中等收入國家之患者更有效的產科與肺部超音波篩檢。
We also signed a contract with [BARDA], a division of the U.S. Department of Health and Human Services develop advanced ultrasound technology with new AI applications for patients with lung pathologies and traumatic injuries. Both of these combined represent over $80 million of committed funding.
我們也與 [BARDA](美國衛生與公共服務部旗下的一個部門)簽署合約,開發先進超音波技術,並導入新的 AI 應用,以用於肺部病理與外傷患者。上述兩項合計代表超過 8,000 萬美元的承諾資金。
Lastly, we announced a strategic collaboration with Mayo Clinic for innovation in medical imaging and theranostics to enhance precision diagnosis and improve patient treatment by using multimodal data, AI and digital health solutions. We're excited about our recent collaborations and how this will help us deliver on our Precision Care strategy.
最後,我們宣布與梅約診所(Mayo Clinic)展開策略性合作,在醫學影像與診療一體化(theranostics)領域推動創新,透過多模態資料、AI 與數位健康解決方案,強化精準診斷並改善病患治療。我們對近期的合作感到振奮,並相信這將協助我們落實精準照護(Precision Care)策略。
The business has demonstrated resiliency and our team has executed this year. We're on track to meet our goals we set at the beginning of the year, and we're making good progress on our mid-range targets. Despite several macro challenges that occurred in 2023, we have been intensely focused on financial and operational execution to deliver on our commitments.
本業務展現韌性,我們的團隊今年也持續有效執行。我們正按計畫達成年初設定的目標,並在中期目標上取得良好進展。儘管 2023 年出現多項總體環境挑戰,我們仍高度聚焦於財務與營運執行,以兌現我們的承諾。
Turning to Slide 3. We delivered strong third quarter performance with 6% year-over-year organic revenue growth driven by volume and price. Importantly, book-to-bill in the quarter was 1.03x, slightly below our book-to-bill of 1.04x in the second quarter. Customer site rising procedure backlog as a reason for capital investments, particularly for products that we offer.
請看投影片 3。我們第三季表現強勁,有機營收年增 6%,主要由出貨量與價格帶動。值得注意的是,本季出貨比(book-to-bill)為 1.03 倍,略低於第二季的 1.04 倍。客戶端據點的手術量待消化積壓上升,成為資本投資的原因之一,特別是針對我們所提供的產品。
Backlog remains robust at $18.4 billion, driven by Services and Imaging products and remains more than $1 billion higher than pre-COVID levels, which gives us confidence in future quarters. Orders growth was 1% versus the same period last year. We recently completed a customer pulse survey in the U.S. and see no significant change in sentiment on capital spending in the second half of 2023 versus the first half of the year.
在服務與影像產品帶動下,積壓訂單(backlog)仍維持強勁,達 184 億美元,且仍較 COVID 前水準高出逾 10 億美元,這讓我們對未來季度更具信心。訂單金額較去年同期成長 1%。我們近期在美國完成一項客戶脈動調查,結果顯示 2023 年下半年相較上半年,在資本支出情緒上沒有顯著變化。
Orders growth can be lumpy in any given quarter, and results do not directly translate to near-term revenue growth. And this is why we give book-to-bill metric as well as total backlog. As it relates to China and the anticorruption campaign, we saw a limited impact to our orders and revenue in the quarter. Both measures were up year-over-year.
訂單成長在任何單一季度都可能呈現波動,且結果不會直接轉化為短期營收成長。這也是我們同時提供出貨比指標與總積壓訂單的原因。就中國與反腐行動而言,本季對我們的訂單與營收影響有限;兩項指標皆較去年同期成長。
We continue to expect a limited impact in the fourth quarter. Also as a reminder, fourth quarter 2022 orders experienced significant growth due to the China stimulus launch last year, which will influence the year-over-year comparisons next quarter. China continues to be an important market with a promising growth profile.
我們仍預期第四季影響有限。另外提醒,2022 年第四季訂單因去年中國刺激措施啟動而大幅成長,將影響下季的年對年比較。中國仍是重要市場,具備可觀的成長前景。
During the quarter, we continued to make steady progress on our productivity initiatives and business optimization using [lean]. For example, delivery performance has improved over 15%, a direct result of implementing pool methodology. The number of purchase components classified as high risk for availability has reduced by approximately 35% year-to-date and customer lead times have improved by more than 15% versus the prior year.
本季我們持續透過 [lean] 推動生產力計畫與業務優化,並穩步取得進展。例如,交付表現提升超過 15%,這是導入 pool 方法論的直接成果。被歸類為供應可得性高風險的採購零組件數量,今年迄今約減少 35%,客戶交期也較去年改善超過 15%。
And lastly, customer satisfaction surveys for service have improved approximately 10% supported by improvement in parts availability and the great efforts by the service team. On the profit line, we generated adjusted EBIT margin expansion while simultaneously accelerating R&D investment. This speaks to our execution capabilities as well as our commitment to funding long-term innovation.
最後,服務客戶滿意度調查提升約 10%,主要受惠於零件可得性改善以及服務團隊的卓越努力。在獲利方面,我們在加速研發投資的同時,仍實現調整後 EBIT 利潤率擴張。這展現了我們的執行能力,也反映我們對資助長期創新的承諾。
Turning to capital allocation. We remain committed to executing an optimized strategy with a focus on creating value for shareholders. Our strong free cash flow generation in the third quarter positions us to be flexible in our capital allocation priorities. We aim to deliver a dividend while continuing to evaluate organic and inorganic investments and deleveraging opportunities.
接著談資本配置。我們仍致力於執行最佳化策略,並以為股東創造價值為核心。第三季強勁的自由現金流,使我們在資本配置優先事項上更具彈性。我們目標是在發放股利的同時,持續評估有機與無機投資,以及去槓桿的機會。
Overall, global markets have remained resilient. Our backlog remains healthy and our team continues to execute. As a result, we're raising the low end of our adjusted 2023 EPS range, representing growth of 11% to 14%.
整體而言,全球市場仍具韌性。我們的積壓訂單維持健康,團隊也持續有效執行。因此,我們上調 2023 年調整後 EPS 指引區間的下緣,對應 11% 至 14% 的成長。
Jay will now take you through our financials and business performance. Jay?
接下來由 Jay 帶各位檢視我們的財務與業務表現。Jay?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Thanks, Pete. Starting with our financial performance on Slide 4. For the third quarter of 2023, revenues of $4.8 billion increased 5% year-over-year and grew 6% organically. This was driven by increased volume and price. Book-to-bill was healthy at 1.03x. Order dollars remain strong and continue to outpace revenues.
謝謝,Pete。先從投影片 4 的財務表現開始。2023 年第三季營收為 48 億美元,年增 5%,有機成長 6%,主要由出貨量增加與價格帶動。出貨比維持健康水準,為 1.03 倍。訂單金額仍然強勁,並持續超過營收。
On a stand-alone basis, third quarter adjusted EBIT margin was 15.4%. Sequentially, margin improved 60 basis points, benefiting from increased volume and productivity actions. Year-over-year, we generated 120 basis points of margin expansion through productivity initiatives and price, partially offset by planned investments and inflation. I'll elaborate on the actions we're taking to expand our margin shortly.
以獨立口徑計算,第三季調整後 EBIT 利潤率為 15.4%。與前一季相比,利潤率提升 60 個基點,受惠於出貨量增加與生產力行動。與去年同期相比,我們透過生產力計畫與定價帶來 120 個基點的利潤率擴張,部分被計畫性投資與通膨所抵銷。我稍後會進一步說明我們為擴大利潤率所採取的行動。
Adjusted EPS was $0.99, down 18% versus prior year due to interest expense but up 14% on a stand-alone basis, driven by increased volume. Free cash flow was up year-over-year due to our strong performance and inventory management.
調整後 EPS 為 0.99 美元,因利息費用較去年同期下降 18%;但以獨立口徑計算則成長 14%,主要由出貨量增加帶動。自由現金流因我們的強勁表現與存貨管理而較去年同期增加。
Moving to Slide 5. Revenues grew 6% organically year-over-year. On a reported basis, product revenue increased 6% year-over-year and service revenue grew 5%. We saw strong organic revenue growth across all regions.
請看投影片 5。營收有機年增 6%。以報導口徑計算,產品營收年增 6%,服務營收年增 5%。我們在所有地區都看到強勁的有機營收成長。
As it relates to margin performance, please turn to Slide 6. Our adjusted gross margin of 41% in the third quarter was strong, driven by pricing and enhanced execution by our commercial teams as well as variable cost productivity initiatives that we're driving. For example, in services productivity, we see lower logistics costs for parts and improved operational rigor.
關於利潤率表現,請看投影片 6。第三季調整後毛利率為 41%,表現強勁,主要由定價、商務團隊更佳的執行力,以及我們推動的變動成本生產力計畫所帶動。例如,在服務生產力方面,我們看到零件物流成本下降,且營運紀律提升。
We also benefited from improving volumes and higher-margin new product introductions. We're optimizing our G&A spend by rationalizing our real estate footprint and also simplifying our IT services and systems across the businesses to create efficiencies as we scale. We've also exited 130 transition service agreements to date.
我們也受惠於出貨量改善以及高毛利新產品導入。我們正透過精簡不動產據點來最佳化 G&A 支出,並在各業務間簡化 IT 服務與系統,以在規模擴張時創造效率。截至目前,我們也已退出 130 份過渡服務協議。
We expect some of the larger scale actions to have a greater impact on results in 2024 and beyond. We've made good progress and remain on track to deliver on our 2023 adjusted EBIT margin expansion guidance. This is primarily driven by gross margin expansion as we continue to invest in R&D, which was approximately 7% of revenues in the quarter.
我們預期部分較大規模的行動將在 2024 年及之後對結果產生更大影響。我們已取得良好進展,並仍按計畫達成 2023 年調整後 EBIT 利潤率擴張指引。這主要由毛利率擴張所驅動,同時我們持續投資研發,本季研發費用約占營收的 7%。
Now let's discuss our segments. Turning to imaging on Slide 7. We generated organic revenue growth of 5% versus the same period last year. This follows several quarters of strong year-over-year revenue growth, reflecting solid backlog and improved fulfillment in price. Revenue growth in the third quarter was driven by MI, CT and MR. This included growth from several new product introductions aimed at driving improved patient outcomes and increased efficiency.
現在讓我們討論各業務分部。請看投影片7的影像(Imaging)業務。我們的有機營收較去年同期成長5%。這延續了過去數季強勁的年對年營收成長,反映出穩健的訂單積壓(backlog)以及在價格實現與交付履約方面的改善。第三季的營收成長主要由MI、CT與MR帶動。其中也包含多項新產品導入所帶來的成長,旨在改善病患治療成效並提升效率。
Segment EBIT margin improved 150 basis points year-over-year as we made progress in driving productivity, price and delivering higher volume, all of this more than offset planned investments. Importantly, EBIT margin also improved 150 basis points on a sequential basis. As previously noted, we expected that it would take a few quarters before pricing measures would catch up to inflation headwinds and we're now seeing that happen.
分部EBIT利潤率年對年提升150個基點,因為我們在提升生產力、價格,以及交付更高出貨量方面取得進展,這些成果皆足以抵銷原先規劃的投資。重要的是,EBIT利潤率也較前一季提升150個基點。如先前所述,我們預期需要幾個季度,定價措施才會追上通膨逆風,而我們現在正看到這一點正在發生。
Turning to Ultrasound on Slide 8. Organic revenue was down 1% year-over-year as we faced a challenging comparison versus the third quarter of 2022 when we delivered double-digit organic revenue growth. Recall that the third quarter last year was the first quarter in which we started to realize improvements in our access to components for this business.
接著看投影片8的超音波(Ultrasound)業務。有機營收年對年下滑1%,因為我們面臨2022年第三季的高基期比較,當時我們實現了雙位數的有機營收成長。請記得,去年第三季是我們開始在該業務的零組件取得方面看到改善的第一個季度。
Looking at the 2-year average, Ultrasound revenue grew in the mid-single digits. The market is stabilizing following COVID and supply chain challenges. We're continuing to execute and maintain our global leadership position. During the quarter, we saw solid demand for newly launched products, in our women's health and cardiovascular businesses.
以兩年平均來看,超音波營收仍以中個位數成長。市場在COVID與供應鏈挑戰後正趨於穩定。我們持續執行並維持全球領導地位。本季我們看到新上市產品需求穩健,尤其在女性健康與心血管業務。
Segment EBIT margin of 22% was down 360 basis points year-over-year, primarily due to planned investments, including cash and health, and inflation. These were partially offset by productivity improvements. Our margin performance reflects our commitment to both organic and inorganic investment as well as technology leadership through AI integration as we seek to enhance precision diagnostics.
分部EBIT利潤率為22%,年對年下滑360個基點,主要因為規劃中的投資(包括現金與健康相關項目)以及通膨所致;部分由生產力改善所抵銷。我們的利潤率表現反映出我們對有機與無機投資的承諾,以及透過AI整合維持技術領先,以提升精準診斷能力。
In the U.S., our venue point-of-care product portfolio now features AI for cardiac exams. This AI guidance technology provides real-time step-by-step guidance to allow even new users to capture diagnostic quality cardiac images. We closed the Caption Health acquisition in February, within 6 months, we incorporated this technology into our portfolio, and we're evaluating other ultrasound use cases to drive future growth.
在美國,我們的Venue床邊照護(point-of-care)產品組合如今已在心臟檢查中導入AI。這項AI引導技術可提供即時、逐步的操作指引,讓即使是新手也能擷取具診斷品質的心臟影像。我們已於2月完成Caption Health的收購;在6個月內,我們就將此技術納入產品組合,並正評估其他超音波使用情境,以帶動未來成長。
Moving to Patient Care Solutions on Slide 9. Organic revenue was up 9% driven by volume and price as we were able to fulfill more backlog. Revenue improved as we continue to realize the benefits of supply chain-related actions taken over the past year. Performance was also driven by contribution from NPIs.
接著看投影片9的病患照護解決方案(Patient Care Solutions)。有機營收成長9%,由出貨量與價格帶動,因為我們得以履行更多的訂單積壓。隨著我們持續實現過去一年採取之供應鏈相關措施的效益,營收有所改善。表現也受到新產品導入(NPI)的貢獻所帶動。
PCS margin increased 120 basis points compared to the third quarter last year, driven by productivity, volume growth and price partially offset by planned investments and inflation. Investments support our monitoring portfolio transformation, which enables broader metrics and device interoperability. We're excited about the new monitoring products that we recently launched and their impact over the next few quarters.
PCS利潤率較去年第三季提升120個基點,主要由生產力、出貨量成長與價格帶動,但部分被規劃中的投資與通膨所抵銷。這些投資支持我們監測產品組合的轉型,使其能提供更廣泛的指標並提升裝置互通性。我們對近期推出的新監測產品以及其在未來幾季的影響感到振奮。
Finally, moving to Pharmaceutical Diagnostics on Slide 10. We had another strong quarter, generating 12% year-over-year organic revenue growth. Segment EBIT margin of 28.2% improved 140 basis points sequentially but declined 230 basis points year-over-year due to raw material inflation and planned investments. This was partially offset by price and productivity actions and volume.
最後看投影片10的藥品診斷(Pharmaceutical Diagnostics)。我們再度交出強勁的一季,有機營收年對年成長12%。分部EBIT利潤率為28.2%,較前一季提升140個基點,但因原物料通膨與規劃中的投資,年對年下滑230個基點;部分由價格與生產力措施以及出貨量所抵銷。
We've seen PDx EBIT margin stabilized and we're encouraged by the strong continued growth of global imaging procedures, which drive the need for contrast agents.
我們看到PDx的EBIT利潤率已趨於穩定;同時,全球影像檢查量持續強勁成長,帶動對顯影劑的需求,這也讓我們備受鼓舞。
Turning to Slide 11. I'll walk through our cash flow performance. We delivered strong results this quarter with free cash flow of $570 million, up $22 million year-over-year. This was driven by better inventory management while absorbing interest and post-retirement benefit payments. Inventory improved versus the prior year period as we continue to leverage lean and solidify our inventory daily management system.
接著看投影片11。我將說明我們的現金流表現。本季我們交出強勁成果,自由現金流為5.70億美元,年對年增加2,200萬美元。這主要來自更佳的存貨管理,同時也吸收了利息與退休後福利給付。相較去年同期,存貨有所改善,因為我們持續運用精實(lean)方法並鞏固每日存貨管理系統。
We're also realizing benefits from easing supply chain constraints and inflationary pressure. We saw solid results in controlling inputs while driving inventory turns for faster revenue conversion through lean events and activities organized across the business. I'm pleased with the fast progress addressing our legacy liabilities and cost structure. In fact, in the past quarter, we were able to achieve agreement to freeze our largest U.S. pension plan, conserving cash that can now be allocated to fund investments to grow our business.
我們也正受惠於供應鏈限制緩解與通膨壓力下降。我們在控制投入成本方面取得穩健成果,同時透過全公司推動的精實活動,加速存貨周轉,以更快將營收轉換為現金。我很高興看到我們在處理歷史負債與成本結構方面進展迅速。事實上,在過去一季,我們已達成協議凍結我們在美國最大的退休金計畫,保留現金,現在可用於支持投資以推動業務成長。
The solid cash flow profile of our business positions us well for continued investment and deleveraging and we remain on track to deliver free cash flow conversion of 85% or more for the full year.
我們業務穩健的現金流特性,使我們能持續投資並去槓桿化(deleveraging);我們仍按計畫在全年達成自由現金流轉換率(free cash flow conversion)85%或以上。
Now let's turn to the outlook on Slide 12. We continue to expect organic revenue growth in the range of 6% to 8%. As a reminder, our fourth quarter organic revenue growth will be compared against a very strong performance of 13% growth in the fourth quarter of 2022.
現在讓我們看投影片12的展望。我們仍預期有機營收成長落在6%至8%的區間。提醒一下,我們第四季的有機營收成長將與2022年第四季非常強勁的13%成長表現相比。
We continue to expect full year adjusted EBIT margin in the range of 15.0% to 15.5% and the adjusted effective tax rate in the range of 23% to 25% for the full year. And given the strong performance to date, we're now raising the low end of our full year 2023 adjusted EPS range to $3.75 to $3.85 versus the prior range of $3.70 to $3.85 per share.
我們仍預期全年調整後EBIT利潤率落在15.0%至15.5%的區間,全年調整後有效稅率落在23%至25%的區間。鑑於目前為止的強勁表現,我們現在將2023年全年調整後EPS區間的下緣上調至每股3.75至3.85美元,先前區間為每股3.70至3.85美元。
With that, I'll hand the call back to Pete.
接下來,我把電話交回給Pete。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Thanks, Jay. Next on Slide 13, I want to touch on a few exciting areas where GE HealthCare is investing to advance our precision care strategy. In Imaging, we continue to make progress on the development of our Photon Counting CT technology. We've added Stanford Medicine as a research partner to scan human subjects on our Photon Counting CT prototype with deep silicone detectors.
謝謝,Jay。接著看投影片13,我想談談GE HealthCare正在投資、以推進我們精準照護策略的幾個令人振奮的領域。在影像業務方面,我們持續推進光子計數CT(Photon Counting CT)技術的開發。我們新增史丹佛醫學(Stanford Medicine)作為研究合作夥伴,將使用搭載深矽(deep silicon)偵測器的光子計數CT原型機對人體受試者進行掃描。
This innovation aims to enhance imaging capabilities and provide clinicians the information and data they need to improve patient outcomes across many care pathways. Photon counting CT technology with deep Silicon unique to GE HealthCare has the potential to go well beyond the capabilities of traditional CT and we look forward to continuing to gather data and incorporate feedback that will move our program forward.
這項創新旨在提升影像能力,並為臨床醫師提供其所需的資訊與數據,以在多種照護路徑中改善病患治療成效。GE HealthCare獨有、採用深矽的光子計數CT技術,具備遠超傳統CT能力的潛力;我們期待持續蒐集數據並納入回饋,以推動我們的計畫向前發展。
In Ultrasound, we recently announced a collaboration with Novo Nordisk to advance the clinical and product development of peripheral focused ultrasound. This marks our introduction into therapeutic ultrasound exploring noninvasive non-pharmacological methods to treat chronic diseases such as type 2 diabetes and obesity.
在超音波方面,我們近期宣布與諾和諾德(Novo Nordisk)合作,推進周邊聚焦超音波(peripheral focused ultrasound)的臨床與產品開發。這標誌著我們進入治療型超音波領域,探索以非侵入、非藥物的方法治療第二型糖尿病與肥胖等慢性疾病。
Encouraging preclinical and early clinical data indicate potential use for people with type 2 diabetes. We are incredibly excited about the potential for this novel technology and its impact on improving patient care.
令人鼓舞的臨床前與早期臨床數據顯示,對第二型糖尿病患者可能具有應用潛力。我們對這項新穎技術及其在改善病患照護方面的影響感到非常興奮。
In PDx, we recently made some exciting announcements to advance our delivery of precision care. For example, we signed a licensing agreement with SOFIE Biosciences for Phase 2 diagnostic tracers. The development of [FAPI] diagnostic targeted agents holds great potential for oncology and other conditions, including inflammation, fibrosis and arthritis by enabling detection of small primary or metastatic lesions.
在PDx方面,我們近期也發布了一些令人振奮的消息,以推進我們提供精準照護的能力。例如,我們與SOFIE Biosciences簽署了第二期(Phase 2)診斷示蹤劑的授權協議。[FAPI]診斷標靶藥劑的開發,透過偵測微小的原發或轉移病灶,對腫瘤學及其他疾病(包括發炎、纖維化與關節炎)具有很大潛力。
Finally, for the second year in a row, we topped the FDA's list with the most artificial intelligence-enabled device authorizations of any med tech company with 58. Through focused R&D spend, we're committed to bringing high-growth innovative technologies to our customers to improve the way health care is delivered. These innovations will create differentiating value for GE HealthCare.
最後,我們連續第二年在FDA榜單中名列第一,成為所有醫療科技公司中獲得最多AI賦能(artificial intelligence-enabled)裝置核准的公司,共58項。透過聚焦的研發支出,我們致力於為客戶帶來高成長、具創新性的技術,以改善醫療照護的提供方式。這些創新將為GE HealthCare創造差異化價值。
Turning to Slide 14. We recently centralized our Care Pathway strategy under our Chief Technology Officer. To us leading our efforts to ensure that we are connecting our products across modalities for each disease state enabled by our digital solutions. On our last earnings call, I touched on this topic of Alzheimer's disease. Today, I'll discuss cardiology as an example, specifically A-Fib, to articulate how our solutions comprehensively address this condition.
接著看投影片14。我們近期已將照護路徑(Care Pathway)策略集中由我們的技術長(Chief Technology Officer)統籌,以領導我們的工作,確保在數位解決方案的支持下,能針對各疾病狀態把跨不同影像/產品模態的產品串聯起來。在上一次法說會中,我提到阿茲海默症這個主題。今天,我將以心臟科為例,特別是心房顫動(A-Fib),來說明我們的解決方案如何全面性地應對此一病症。
A-Fib, as many of you may know, is the most common arrhythmia diagnosed in clinical practice affecting millions of people worldwide. It's often misdiagnosed or not treated appropriately with up to 30% of cases missed in routine clinical exams.
心房顫動(A-Fib),如各位所知,是臨床實務中最常被診斷的心律不整,影響全球數百萬人。它經常被誤診或未獲得適當治療,在例行臨床檢查中多達 30% 的病例會被漏診。
To advance our A-Fib care pathway, we recently launched CardioVisio, which integrates, organizes and visualizes longitudinal patient data from multiple devices. Taking this data along with current guidelines from the American College of Cardiology, we were able to provide evidence-based clinical decision support from detection through monitoring.
為了推進我們的心房顫動照護流程,我們近期推出了 CardioVisio,可整合、整理並視覺化來自多種裝置的患者縱向資料。結合這些資料以及美國心臟學會(American College of Cardiology)的現行指引,我們得以提供以證據為基礎的臨床決策支援,涵蓋從偵測到監測的全流程。
CardioVisio connects and presents the most relevant patient data from across the care pathway. And this helps to save time and identify more patients eligible for recommended therapies. This launch is an important step on our journey to integrate devices and digital solutions to assist cardiologists and caring for patients across the entire cardiovascular care pathway.
CardioVisio 能串聯並呈現照護流程中最相關的患者資料。這有助於節省時間,並辨識出更多符合建議治療資格的患者。此次推出是我們旅程中的重要一步,將裝置與數位解決方案整合,以協助心臟科醫師,並在整個心血管照護流程中照護患者。
In the future, we plan to expand CardioVisio to address additional areas such as coronary artery disease and structural heart. We also expect to launch similar innovations to support oncology and neurology by linking multi-vendor devices, digital and disease-based solutions to better serve our customers and drive growth.
未來,我們計畫擴展 CardioVisio,以涵蓋更多領域,例如冠狀動脈疾病與結構性心臟病。我們也預期推出類似創新以支援腫瘤科與神經科,透過連結多供應商裝置、數位與疾病導向解決方案,更好地服務客戶並推動成長。
Turning to Slide 15. In summary, we've made substantial financial and operational progress year-to-date, demonstrating that our strategy is working. Our team continues to execute, and I'd like to thank all of our employees across the world for their dedication and efforts.
接著看第 15 張投影片。總結而言,我們今年迄今在財務與營運方面已取得顯著進展,證明我們的策略正在奏效。我們的團隊持續落實執行,我也要感謝全球所有員工的投入與努力。
Before taking your questions, I want to highlight the recent release of our first sustainability report since becoming an independent company. Corporate responsibility is core to our vision and it embodies our purpose to create a world where health care has no limits. To learn more about our sustainability goals and future plans, visit our ESG page on our website. With that, let's open up our call to questions.
在回答各位問題之前,我想強調我們近期發布了自成為獨立公司以來的第一份永續報告。企業責任是我們願景的核心,也體現了我們的使命:打造一個醫療照護無界限的世界。若要進一步了解我們的永續目標與未來計畫,請造訪我們網站上的 ESG 頁面。接下來,我們開放提問。
Carolynne Borders - Chief IR Officer
Carolynne Borders - Chief IR Officer
Thank you, Peter. (Operator Instructions). Operator, can you please open the line?
謝謝你,Peter。(接線員指示)。接線員,請開放線路好嗎?
Operator
Operator
(Operator Instructions) Our first question comes from Vijay Kumar with Evercore.
(接線員指示)我們的第一個問題來自 Evercore 的 Vijay Kumar。
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Congratulations and good execution here. I did want to touch upon your order commentary here. What was that China in the quarter? And can you quantify what the order growth was for your capital book of business? And if you can have those numbers ex China, I think there's some debate on how big of a deal is China to order.
恭喜,執行得很好。我確實想談一下你們對訂單的評論。本季中國的情況如何?你能量化一下資本設備業務(capital book of business)的訂單成長是多少嗎?如果能提供剔除中國後的數字更好,我想市場對於中國對訂單的重要性到底有多大仍有一些爭論。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, Vijay, let me -- I'll start at a high level and then see Jay wants to add some comments. I'd just start by saying that we're continuing to see solid end market demand really around the world, including China, and I'll talk about that a little bit more specifically, Again, if you step back, you'll recall that in '21, '22 as customers, all of us were coming out of COVID, we saw really strong demand in different products from an orders growth standpoint. Ventilators, obviously, but CT, ultrasound, monitoring for continuous monitoring.
好的,Vijay,讓我——我先從較高層次開始,然後看看 Jay 是否想補充一些評論。我先說,我們持續看到全球終端市場需求穩健,包括中國,我會再更具體談一點。再退一步看,你會記得在 21 年、22 年,當客戶、我們所有人都走出 COVID 時期時,從訂單成長角度來看,我們在不同產品上看到非常強勁的需求。當然包括呼吸器,但也包括 CT、超音波,以及用於連續監測的監護設備。
And then that was followed by 2023 this year, which is essentially a transition year with tougher comparisons. But that's what we planned for. And so as we look ahead here, really going even into '24, we're expecting that to be kind of the first year with more of a normalized market environment since COVID, which we obviously view as very positive.
接著是 2023 年,也就是今年,基本上是一個在更嚴苛比較基期下的過渡年。但這正是我們所規劃的。因此展望未來,甚至進入 24 年,我們預期那將是自 COVID 以來市場環境更趨正常化的第一年,而我們顯然認為這非常正面。
So relative to Q3, it's been as kind of printed market, I would say, is how we've seen things. If you switch over to your point on China, I'd say we saw a limited impact to orders and sales in Q3. As I mentioned in the comments here, we were actually up in orders and sales over '22 in Q3 and we expect limited impact in Q4. So it's good results overall there. And I'm just proud of eHow and our team in China really did a really nice job and worked through some tough challenges as you can imagine. We're starting to see signs of the anticorruption campaign stabilize here. We started to -- in late September. I think a lot of market events in early August were kind of stopped, but then resumed by October. There was a recent anesthesia congress that all reports was back to full capacity, whereas certain meetings early were low.
所以相較於第三季,市場表現大致如同呈現出來的那樣,這是我們的觀察。回到你提到的中國,我會說第三季對訂單與銷售的影響有限。如我在評論中提到的,我們第三季的訂單與銷售相較於 22 年其實是成長的,而且我們預期第四季影響也有限。因此整體結果不錯。我也為 eHow 以及我們在中國的團隊感到自豪,他們確實做得很好,並如你所想像地克服了一些艱難挑戰。我們開始看到反貪腐行動趨於穩定的跡象,大約從 9 月下旬開始。我認為 8 月初的許多市場活動一度停擺,但到 10 月又恢復。最近有一場麻醉學大會,據各方回報已恢復到滿場,而較早期的一些會議出席率偏低。
So we believe that we're going to see a similar kind of trend here continue on in the fourth quarter.
因此我們相信,第四季將會延續類似的趨勢。
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team
Understood. And I had one follow-up here on margins, perhaps both for you and Jay. I think clearly, you mentioned products like CardioVisio, AI solutions. How do you price these solutions? And what's the margin profile for these kinds of products and related to margins, I think you mentioned price caught up with inflation. Is that something we should be expecting to sustain into fiscal '24?
了解。我還有一個關於毛利率的追問,可能想請你和 Jay 都回答。我想很明顯地,你提到像 CardioVisio、AI 解決方案等產品。你們如何為這些解決方案定價?這類產品的毛利結構如何?另外就毛利率而言,我記得你提到價格已追上通膨。這是否是我們應該預期在 24 財年仍能持續的情況?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, Vijay, maybe I'll start and then, Jay, you can talk a little bit more about price. So we're still early innings on the AI monetization, but it's super exciting. Obviously, we're humbled to be in one of the leadership roles to have new applications out. But the way we think about the start is AI inside our products, which is really across our portfolio now, as those products come out, they will bring, in some cases, 3, 4, 5-plus points of margin accretion on a given product to enable that.
好的,Vijay,我先回答,然後 Jay 也可以再談談價格。我們在 AI 變現方面仍處於早期階段,但非常令人振奮。顯然,我們很謙卑能在領導者之一的位置推出新的應用。我們的起步方式,是把 AI 內建在產品中,而這現在已遍及我們的產品組合;隨著這些產品推出,在某些情況下,AI 會讓單一產品的毛利提升 3、4、5 個百分點甚至更多。
I think our example that we talk about is an MR, where an MR system that has Air Recon DL and it has quite a bit of step-up of margin over one that doesn't. And so that's going to continue to grow. As we bring something like CardioVisio in which you mentioned, which again, we're just beginning to roll out as kind of a core offering that will go across many products and will incorporate AI over time, that will be a SaaS model, where it will be a reoccurring revenue model.
我們常舉的例子是 MRI:搭載 Air Recon DL 的 MRI 系統,相較於未搭載者,毛利有相當幅度的提升。因此這將持續成長。至於你提到的 CardioVisio,我們才剛開始將其作為核心產品推出,未來會橫跨多種產品,並隨時間納入 AI;它將採用 SaaS 模式,也就是經常性收入模式。
I would say we will price it based on value structure. And from a margin standpoint, we would expect that to have typical software margins, something north of 75%, 80% in that range. And so this is going to be a couple year evolution as we grow this. But this, again, we believe, is the future of multimodal data and really adding value to help solve customers' issues. So Jay, maybe you want to comment about price.
我會說,我們會依據價值架構來定價。就毛利而言,我們預期會有典型軟體毛利率,大約在 75%、80% 以上的區間。因此這會是我們在未來幾年逐步演進與擴張的過程。但我們相信,這代表多模態資料的未來,也能真正增加價值,協助解決客戶的問題。Jay,你或許可以評論一下價格。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. Vijay, we previously discussed expecting price impacts on sales this year in the 2% to 3% range. And then over the midterm plan that we've laid out, continuing to see 1% to 2% price. And a lot of that is about the execution framework we have in place, a culture around disciplined in pricing. And all of those ingredients are intact. So I would say we're very much on track for the 2% to 3% this year, and we see signs that support the longer-term execution pathway that we previously laid out.
好的。Vijay,我們先前討論過,今年價格對銷售的影響預期在 2% 到 3% 的區間。接著在我們提出的中期計畫期間,將持續看到 1% 到 2% 的價格提升。其中很大一部分來自我們既有的執行架構,以及在定價上保持紀律的文化。這些要素都仍然到位。因此我會說,我們今年非常符合 2% 到 3% 的目標,而且我們也看到一些跡象支持我們先前所提出的長期執行路徑。
Operator
Operator
Our next question comes from Joanne Wuensch with Citi.
我們的下一個問題來自 Citi 的 Joanne Wuensch。
Joanne Karen Wuensch - MD
Joanne Karen Wuensch - MD
This is the time of the year we start looking forward. And I'm curious about a couple of things. In any particular order, how you're feeling about 2024, street revenue consensus or mid-single digits. And is there anything about the order book year-to-date that would imply or give implications for 2024 that you can share now?
每年這個時候我們開始展望未來。我對幾件事很好奇,不分先後:你們對 2024 年的看法如何?市場對營收共識大約是中個位數成長。以及,今年迄今的訂單簿是否有任何跡象或含意,能讓你們現在就分享對 2024 年的啟示?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Joanne, thanks for the question. The -- we're going to -- we'll stop short of giving guidance at this point, but I would say that -- I would say a few things that can provide some color. First, really pleased with the execution so far this year. I think our continued focus on orders execution, our continued focus on sales execution and margin enhancement really do set the stage for successful delivery of 2024 and beyond.
Joanne,謝謝你的問題。我們——目前先不提供指引,但我會說——我會提幾點作為補充說明。第一,我們對今年迄今的執行表現非常滿意。我認為我們持續聚焦於訂單執行、持續聚焦於銷售執行與毛利提升,確實為 2024 年及之後的成功交付奠定了基礎。
Secondly, I would point to the backlog that we have in place. The backlog from Q2 to Q3 was essentially flat despite 6% revenue growth. And a lot of that comes down to a book-to-bill that's continued to be in excess of 1. And so we're really happy with the backlog that's set up for 2024.
其次,我會指出我們目前的在手訂單(backlog)。從第二季到第三季,在營收成長 6% 的情況下,在手訂單基本持平。而這在很大程度上是因為訂單出貨比(book-to-bill)持續高於 1。因此,我們對於為 2024 年所建立的在手訂單感到非常滿意。
The final thing I would say is we do regularly survey customers. Pete alluded to some of this. And we're seeing a decent backdrop set up for 2024. I think all of these elements are key ingredients and successfully delivering 2024. And so we're very focused on that as we go through our planning process in the coming weeks and months. Pete, anything to add?
最後我想說的是,我們會定期對客戶進行調查。Pete 也提到了一部分。我們看到 2024 年的整體環境基調相當不錯。我認為這些要素都是成功交付 2024 年的關鍵成分。因此,在接下來幾週與幾個月的規劃流程中,我們會非常專注於此。Pete,還有要補充的嗎?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
No, I think you covered it. I think the point about the customer feedback is really the most important part. I mean, Jay and myself, obviously, our old teams get out quite a bit around the world. And talk one-on-one with CEOs and leaders of health systems. And again, both the commentary as well as our surveys that we do routinely kind of lean to the fact that second half compared to first half is very consistent on market and capital outlook.
沒有,我覺得你都涵蓋到了。我認為關於客戶回饋的重點其實是最重要的部分。我的意思是,Jay 和我,當然,我們各自的團隊在全球各地跑得很勤。並且與醫療體系的 CEO 與領導者一對一交流。再者,無論是這些評論,還是我們例行進行的調查結果,都傾向顯示:下半年相較上半年,在市場與資本展望方面是非常一致的。
We're not a company that's typically driven by procedures, but obviously, the procedures drive our business, and that continues to be strong. And then I would say we're hearing more and more incremental positive views about '24 from customers. You've seen prints recently from some customers, but also just from a standpoint of -- with their aging installed base and the procedural growth, many customers are thinking ahead about their needs in future. And obviously, we see this as a healthy outlook. So we're optimistic about how we see making the turn into '24.
我們通常不是一家由手術量(procedures)驅動的公司,但顯然手術量會帶動我們的業務,而這仍然很強勁。接著我會說,我們從客戶那裡聽到越來越多對 2024 年的增量正面看法。你最近也看到一些客戶的公開數據(prints),但同時從另一個角度來看——隨著他們老化的已安裝基礎(installed base)以及手術量成長,許多客戶正在提前思考未來的需求。顯然,我們認為這是一個健康的展望。因此,對於我們邁入 2024 年的轉折,我們是樂觀的。
Operator
Operator
Our next question comes from Anthony Petrone with Mizuho.
下一個問題來自瑞穗(Mizuho)的 Anthony Petrone。
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
Congrats on another strong quarter here. I think I'll stay on the 2024 theme and maybe just to level set where the backlog conversion to forward revenues sort of sits on maybe an 18-month go-forward basis. So as we look at the ending backlog, is it -- should we be thinking that it's feasible that 60% of the backlog can be converted over the next 18 months? And are there any areas where that backlog conversion possibly got extended. We heard some competitors talking about elongated cycles, for instance, in China. And I'll have a quick follow-up for Jay on margins.
恭喜又一個強勁的季度。我想我會延續 2024 年這個主題,或許先校準一下:在手訂單轉換為未來營收的大致位置,從未來約 18 個月的角度來看是如何。因此,當我們看期末在手訂單時——我們是否應該認為,在未來 18 個月內將 60% 的在手訂單轉換出來是可行的?另外,有沒有任何領域的在手訂單轉換可能被拉長?例如,我們聽到一些競爭對手談到週期拉長,像是在中國。我還有一個關於毛利的追問要問 Jay。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, Anthony, I would say when we think about our backlog, we actually felt it's quite solid. I mentioned that it was $18 and change -- $18.4 billion. with book-to-bill, you know how the math works, as we actually are having a book-to-bill that's positive, meaning that it's actually more orders are going in than revenues going out. We'll start next year with a backlog that's pretty close to where we are today, which is super healthy. And it's about $1 billion above where we were pre-COVID.
是的,Anthony,我會說當我們看待在手訂單時,我們其實覺得相當穩健。我提到它是 180 億多——184 億美元。以訂單出貨比來看,你知道數學怎麼算,因為我們的訂單出貨比是正的,代表進來的訂單其實比流出的營收更多。我們明年年初的在手訂單會與現在非常接近,這非常健康。而且比我們 COVID 前高出約 10 億美元。
So that gives you plenty of gas in the tank to be able to continue to drive revenue. And again, with this business that can be lumpy on the orders front, that's an important dynamic. I mentioned in China. I know there's been a lot of different news from different companies. We obviously felt the effects of the China anticorruption earlier about customers disengaging at some level, but as that reintegrated in later in the quarter, obviously, we put up good numbers with being able to outperform the previous year.
所以這讓你有充足的「油箱」可以持續推動營收。而且再次強調,這個業務在訂單端可能會有波動,因此這是一個重要的動態。我剛提到中國。我知道不同公司有很多不同的消息。我們確實在較早時候感受到中國反貪腐的影響,客戶在某種程度上有些抽離,但隨著在本季後段重新回流,顯然我們交出了不錯的數字,並且能夠優於去年。
The only other comment I would say relative to Q3, in the U.S. towards the end of the quarter, we did see some longer deals taking a little bit longer. And as you kind of peel the onion back on that, what it really is about is that some customers are seeing some higher project costs more on the labor and construction side for install compared to their initial budgets.
另外一點我想說的是,與第三季相關,在美國於季末時,我們確實看到一些較長週期的交易花了更久時間。當你把這件事層層剖析後,實際上是因為部分客戶在安裝專案上,勞務與施工端的成本相較於他們最初的預算更高。
And so the deals are getting done for sure. But what that means is they may have to go back to their finance committee and say, "Hey, this is going to be $100,000 more and actually get another approval". And so I think that works its way through the systems as those estimates and the actual cost match up in the coming quarters. But that's probably the only thing we've seen that has kind of played out on the time horizon.
因此,交易當然還是會成交。但這代表他們可能需要回到財務委員會說:「嘿,這會多 10 萬美元,並且需要再取得一次核准。」所以我認為,隨著這些估算與實際成本在接下來幾季逐步對齊,這個情況會在系統中被消化。但這大概是我們看到在時間軸上有所影響的唯一因素。
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst
Very helpful. And quickly, Jay, just on the implied 4Q earnings, would be $0.09, midpoint is up by $0.02 for 4Q. So just anything of note and as we look into the back end of the year here for the margin trajectory? And if there are any headwinds that we're seeing, do those potentially slip into the first half of '24. Again, congratulations.
非常有幫助。再快速問一下,Jay,關於第四季隱含的每股盈餘,大概是 0.09 美元,中位數對第四季上調了 0.02 美元。所以在今年後段的毛利走勢上,有沒有什麼值得注意的?如果我們看到任何逆風,那些是否可能延續到 2024 年上半年?再次恭喜。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Yes. Thank you -- thanks for the question and the comment. Overall, we're pleased with the performance year-to-date. I think what we've seen across the board is the resiliency of the portfolio, continued focus on margin execution. I think all the key ingredients are in place. By the way, I would also point out very strong free cash flow performance in the third quarter, which is an intense area of focus for us. So I feel very good about what we delivered in the third quarter.
是的。謝謝——也謝謝你的問題與評論。整體而言,我們對今年迄今的表現感到滿意。我認為我們看到的是整體產品組合的韌性,以及對毛利執行的持續聚焦。我覺得所有關鍵要素都已到位。順帶一提,我也要指出第三季自由現金流表現非常強勁,這是我們高度聚焦的領域。所以我對第三季的交付成果感覺非常好。
As we move to the fourth quarter, the probability -- our confidence in our ability to achieve the full year outlook has definitely increased. We raised the low end by $0.05, which implies $0.025. We don't really have material changes to the fourth quarter outlook. We feel solid about that. I would point out that there were a couple of cents of FX. The way our FX forecast worked out and the subsequent rate moves, we had a bit of favorability in EBIT in the third quarter related to foreign exchange, a couple of cents. And then the fourth quarter is a couple of cents lighter than the forecast we put together. That's the most noteworthy item.
當我們進入第四季時,我們達成全年展望的機率——也就是我們的信心——確實提高了。我們把低端上調了 0.05 美元,這隱含約 0.025 美元。我們對第四季展望並沒有實質性的變動。我們對此感到踏實。我會指出,有幾美分來自匯率(FX)。依我們的匯率預測以及後續匯率變動,我們在第三季的 EBIT 因外匯而有一些有利影響,大概幾美分。而第四季則比我們當初做的預測少了幾美分。這是最值得注意的一點。
Other than that, I think we're going to focus on continued execution in the fourth quarter and setting ourselves up for a successful 2024.
除此之外,我認為我們會專注於第四季的持續執行,並為成功的 2024 年做好準備。
Operator
Operator
Our next question comes from Patrick Wood with Morgan Stanley.
下一個問題來自摩根士丹利(Morgan Stanley)的 Patrick Wood。
Patrick Wood
Patrick Wood
I mean taking a step back, historically, it was tough to get paid for innovation. You have the slice wars and then you add Freelium, and it was always kind of difficult to get price. But today, you guys did a great job in taking price mix on some of the recent innovations. I guess my question is like what do you think has changed? Is it just that the scope of innovation happening today is higher? And how should we interpret that so how you're thinking about pricing for photon counting longer term?
我的意思是,退一步看,過去要為創新收費一直很難。你有切片戰爭(slice wars),再加上 Freelium,想要拿到價格總是有點困難。但今天,你們在一些近期創新上把價格組合(price mix)做得很好。我想問的是,你覺得改變了什麼?是因為當今的創新幅度更大嗎?那我們應該如何解讀——也就是你們長期對光子計數(photon counting)定價的思考?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, Patrick, great question. Look, I think it's a convergence of many different things. Obviously, with the higher cost that took place during the COVID window, sometimes that's a necessity for all to kind of reflect on your pricing strategies and where you are. And so I think that's some level of a beginning catalyst. It's been a really important part of our kind of strategy as a company to talk about that we want to be paid fairly for what we come up with.
是的,Patrick,這是個好問題。你看,我認為這是許多不同因素的匯聚。顯然,在 COVID 期間發生的成本上升,有時會成為一種必要性,讓所有人重新檢視自己的定價策略與所處位置。所以我認為那在某種程度上是最初的催化劑。作為公司策略的一部分,談到我們希望對我們所提出的成果獲得公平的報酬,這一直是非常重要的一環。
I think when you look at the ROI on many of the products we make, they pay for themselves in months, not years. And many of these products are held for 7 to 8 years. So the return on investment, whether you're paying 2% money or 8% money is still very, very good. And I think that's part of it. And getting the confidence in your commercial teams that that's the reality and how to sell that value, I think that's been part of it.
我認為,當你看我們許多產品的投資報酬率(ROI),它們是以「幾個月」而不是「幾年」就能回本。而且許多這些產品會被使用 7 到 8 年。所以無論你付的是 2% 的資金成本或 8% 的資金成本,投資報酬仍然非常、非常好。我認為這也是其中一部分。並且讓商務團隊建立信心:這就是現實,以及如何銷售這個價值,我認為這也是其中一部分。
The other aspect is innovation investments. If you're innovating and coming out with something every 3 to 5 years versus something new every 18 months that you can actually ask a little bit more for because it actually creates more value, that also brings price up. And that's an important part of our strategy. But at the end of the day, we have to demonstrate that we bring more value for customers and show that the returns are there. And I think things such on the digital side and artificial intelligence that can actually reduce workflow issues. It can actually take work out of the system and actually can treat more patients is a winner.
另一個面向是創新投資。如果你在創新,並且每 3 到 5 年推出一些新東西,相較於每 18 個月就推出一個新東西,而你實際上可以因為它確實創造了更多價值而多收一點費用,這也會推升價格。而這是我們策略中很重要的一部分。但歸根結底,我們必須證明我們為客戶帶來更多價值,並展示回報確實存在。我認為像是數位化與人工智慧這一類的事情,實際上可以減少工作流程的問題。它確實可以把工作從系統中移除,並且實際上能夠治療更多病患,這就是贏家。
We talked about Air Recon DL. You have a 10-year-old product. We do an upgrade. We actually ask a reasonable value for that that's higher margin than we would typically get on just a hardware alone. And you get a 50% increase in throughput, and we also take your capabilities to state-of-the-art. Those are the kind of things that we're excited about. And I think more of the software applications and capabilities we have coming forward are going to deliver on that.
我們談到 Air Recon DL。你有一個 10 年前的產品。我們做一次升級。對此我們實際上會收取合理的價值費用,而其毛利率高於我們通常僅靠硬體本身所能取得的水準。你可以獲得 50% 的吞吐量提升,我們也把你的能力提升到最先進水準。這些就是我們感到興奮的事情。我認為我們接下來推出的更多軟體應用與能力,將會在這方面交付成果。
Patrick Wood
Patrick Wood
Just as a very quick follow-up. Are you seeing anything notable on spec. I mean, like maybe with some of the bundled deals, a higher proportion of free Tesla or like anything on the spec across the different modalities.
再非常快速追問一下。你們在規格(spec)方面有看到什麼值得注意的變化嗎?我的意思是,例如在一些綑綁式交易中,免費 Tesla 的比例更高之類的,或是在不同模態之間的規格配置上有任何變化?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
When you say spec, you're talking about different specifications on the modalities changes?
你說的 spec,是指各個模態的不同規格變化嗎?
Patrick Wood
Patrick Wood
Yes, because obviously not every MR and CT scanners equivalent. And obviously, with -- especially with some of the bundled deals, I'm curious as to how people are bundling purchasing and less direct pricing or the systems themselves that they're buying within those?
是的,因為顯然不是每一台 MR 和 CT 掃描儀都等同。而且很明顯地,特別是在一些綑綁式交易中,我很好奇大家在採購綑綁時是怎麼搭配的——相較於直接對系統本身定價,他們在那些交易裡實際買的是哪些系統?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes. I think, look, it's -- what's becoming and as you know, in this industry, there are very few kind of brand-new customers to imaging, right? If you just take imaging and even take monitoring or anesthesia out of it. And so there tends to be a much larger fleet discussion that takes place. You don't need state-of-the-art everywhere, but you need workforce systems in certain parts, whereas you may need certain really cutting-edge capabilities in other areas. I mean this whole Alzheimer's discussion that we're kind of helping sure for certain customers through on their fleet is where do you need the PET capabilities at? Where do you need the certain MR capabilities? How is that tied to infusion center. There's a lot more of that discussion going on. and it tends to be a little bit more of a heterogeneous installed base based on needs.
是的。我想,重點是——而且如你所知,在這個產業裡,影像領域幾乎沒有那種全新的客戶,對吧?如果你只看影像,甚至把監測或麻醉先排除在外。因此,通常會有更大規模的機隊(fleet)層面的討論。你不需要每個地方都用最先進的設備,但你在某些區域需要能支撐工作量的系統,而在其他區域你可能需要一些真正尖端的能力。我的意思是,我們正在協助某些客戶在其機隊中推進的這整個阿茲海默症(Alzheimer's)討論,就是:你在哪裡需要 PET 能力?你在哪裡需要某些 MR 能力?這如何與輸注中心(infusion center)連結?這類討論正在變得更多,而且基於需求,已安裝基礎(installed base)往往會更異質化。
But again, that's how we can demonstrate how do you match up what you're trying to achieve Mr. customer with which products that you need. And so this idea of a multisite fleet strategy is becoming more and more part of what we do, both domestically as well as big markets around the world.
但再說一次,這正是我們能夠證明的地方:你想達成什麼,客戶先生(Mr. customer),以及你需要哪些產品來匹配。因此,這種多據點機隊策略(multisite fleet strategy)正越來越成為我們工作的核心之一,無論是在國內,還是在全球各大市場。
Operator
Operator
Our next question comes from Larry Biegelsen with Wells Fargo.
我們的下一個問題來自富國銀行(Wells Fargo)的 Larry Biegelsen。
Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst
Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst
Sorry, one more on orders. I continue to get e-mails from people on this. So I'm going to ask you originally expected mid-single-digit order growth in 2023. Is that still the case? And if not, just help us understand how you can grow revenues mid-single digits in 2024 if order growth is below that? Or how does order growth translate? Why doesn't it translate into revenue growth the following year? And I had one follow-up on margins.
抱歉,再問一個關於訂單(orders)的问题。我一直收到很多人就此寄來的電子郵件,所以我想問:你們原先預期 2023 年訂單成長為中個位數(mid-single-digit)。現在仍然是這樣嗎?如果不是,請幫我們理解:如果訂單成長低於這個水準,你們如何在 2024 年仍能讓營收成長中個位數?或者說,訂單成長如何轉化?為什麼它不會轉化為隔年的營收成長?另外我還有一個關於毛利率的追問。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. So Larry, in terms of order growth, I think one of the key things to consider is the book-to-bill ratio. We are still in excess orders in excess of sales by a margin of 1.03x this quarter. And we expect, over time, that's something that we've seen for essentially the last 7 or even more quarters. We've seen very robust book-to-bill ratio. And what that does is it allows us to set up a backlog, which can allow for successful execution on sales in future years. So I think for us, there's always volatility in a given quarter on orders. We've discussed that as it relates to this particular quarter. But overall, we feel quite good about what we've been able to execute on from both an order standpoint, from a book-to-bill standpoint and then also a high-quality backlog standpoint.
好的。Larry,就訂單成長而言,我認為需要考量的一個關鍵是接單出貨比(book-to-bill ratio)。本季我們仍然是訂單高於銷售,比例約為 1.03 倍。而且我們預期,隨著時間推進,這也是我們基本上在過去 7 季甚至更久所看到的情況。我們看到非常強勁的接單出貨比。而這帶來的效果是,它讓我們能建立在手訂單(backlog),進而支持未來年度成功執行銷售。因此對我們而言,單一季度的訂單總會有波動。我們也已就本季的情況討論過。但整體而言,我們對於在訂單、接單出貨比,以及高品質在手訂單這三方面的執行成果都感到相當不錯。
I think those are the three ingredients all of which that we have to look at in conjunction with one another when we look at the health of the portfolio and the revenue projections that we have in place. So I think really, that's the overall story. We don't really give orders guidance per se. It's something that we target over time. But we feel good about the setup. And furthermore, as we think about how customers are feeling the surveys that we've done and also the customer reports that we're seeing indicate that the backdrop should be pretty good going into next year. So I don't know those would be a few comments that I'd make. Pete, I don't know if you want to add anything.
我認為,當我們評估產品組合的健康度以及我們所設定的營收預測時,這三個要素必須結合起來一起看。所以我想,整體故事就是如此。我們並不會逐項提供訂單指引(orders guidance)。這是我們長期追求的目標。但我們對目前的布局感到良好。此外,當我們思考客戶的感受時,我們做的調查以及看到的客戶回饋都顯示,進入明年時的外部環境應該會相當不錯。所以,大概就是我會補充的幾點。Pete,你要不要再補充?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, I think you hit it. I think the key here is that the backlog is very healthy and that we exit the year with really the same level, if not larger backlog than how we started. So we're in that same range, again, which gives us confidence going forward. I would point out, PDx continues to be strong as well, which actually isn't a backlog business, but that's a continual contract business as well as service growth. I mean we talked about last year gaining some share continuing to do so as we started this year. And the benefit of that is once the warranty period rolls off, [113], you move into contracts. And so that's beginning to drive more service growth, which has higher margins. It also has multiyear continuum to it.
是的,我覺得你說到重點了。關鍵在於在手訂單非常健康,而且我們在年底結束時的在手訂單水位,基本上與年初相同,甚至更高。所以我們仍在同一個區間,這也再次讓我們對未來更有信心。我也想指出,PDx 依然強勁,而這其實不是一個在手訂單型的業務,但它是持續性的合約業務,同時也帶動服務成長。我們提到去年我們取得了一些市占,且在今年年初仍持續如此。其好處是,一旦保固期結束,[113],你就會轉入合約。因此這開始推動更多服務成長,而服務的毛利率更高,而且具有多年期的延續性。
So about half of our revenues are capital, so to speak, on a win basis on -- of the week, whereas the rest of the business is actually recurring. So we feel good, Larry, about the position of where we're at right now, all things considered in the world.
因此,我們大約一半的營收可以說是資本性(capital)的、以中標(win)為基礎——以週為單位來看——而其餘的業務其實是經常性(recurring)的。所以 Larry,綜合當今世界各種因素,我們對目前所處的位置感到不錯。
Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst
Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst
That's super helpful. And on the margins, the company talked about getting to high teens to 20% adjusted EBIT margin over the medium term, which I think you guys defined is 3 to 5 years from '22 or '23. And before we initiated coverage, Jay, the company defined that, I think, is about 17% in 2025, 20% in 2027. Has anything changed? Are those still the goals? And is there any reason margins shouldn't increase next year?
這非常有幫助。關於利潤率,公司談到在中期達到調整後 EBIT 利潤率高十幾到 20%(high teens to 20%),我理解你們定義的中期是從 2022 或 2023 年起算的 3 到 5 年。在我們開始覆蓋之前,Jay,公司曾定義我記得是 2025 年約 17%,2027 年 20%。有任何改變嗎?這些仍然是目標嗎?另外,有沒有任何理由讓利潤率明年不應該上升?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. I think as I've spent a lot of time on margin since joining the company a few months ago. And what I would say is we feel quite good about the margin plan. It starts with this culture of lean at the company. I've been really impressed with this idea, the lean mindset and how we're driving operational execution improvements across the board. And so that's culturally an important backdrop.
好的。我想,自從幾個月前加入公司以來,我在利潤率上花了很多時間。我會說的是,我們對利潤率計畫感到相當有信心。它始於公司內部的精實(lean)文化。我對這個概念印象很深刻——精實思維,以及我們如何在各方面推動營運執行的改善。因此,這在文化上是一個重要的背景。
We've previously outlined three drivers of margin enhancements, and I think all of them are intact. First, commercial execution. We've talked a lot about pricing today. It's a real area of focus for us in all of our business reviews, and we've seen dividends this year, and we expect continued pricing impact.
我們先前概述過利潤率提升的三個驅動因素,我認為它們都仍然成立。第一是商業執行。我們今天談了很多定價。這是我們在所有業務檢討中真正聚焦的領域,我們今年已看到成效,並且預期定價帶來的影響會持續。
The second area of focus is innovation. New products being introduced with higher margins. Pete talked about that earlier today. And we've seen that across the board, and we talked about that extensively during the prepared remarks.
第二個聚焦領域是創新。推出毛利率更高的新產品。Pete 今天稍早也提到過。我們在各個面向都看到了這點,而且我們在事先準備的發言中也對此做了充分說明。
And then finally, this idea of optimization. And optimization comes in a lot of different ways, productivity, variable cost productivity initiatives that we have in place managing spot buys, managing logistics costs, managing G&A costs as well. Those are all clear areas of focus for us. And what I would say is on a year-to-date basis, we feel quite good. The third quarter was up 120 basis points over the prior year.
最後是這個「最佳化」的概念。最佳化有很多不同的方式:生產力、我們正在推動的變動成本生產力計畫、管理現貨採購、管理物流成本,以及管理 G&A 成本。這些都是我們明確的重點聚焦領域。我想說的是,以年初至今的基礎來看,我們感覺相當不錯。第三季相較前一年提升了 120 個基點。
We were able to execute on a few different areas of margin enhancement. And by the way, Larry, we were able to grow R&D a very significant amount. So what we're trying to do is drive productivity and efficiency at the company, while at the same time, protecting dollars for investment in growth in areas like R&D. So far so good, and we look forward to continuing to -- on that path as we move forward.
我們在幾個不同領域執行了毛利提升。順帶一提,Larry,我們也讓 R&D 大幅成長。因此我們想做的是:在推動公司生產力與效率的同時,也要保護用於成長投資(例如 R&D)的資金。到目前為止進展良好,我們也期待在往前走的過程中,持續沿著這條路徑前進。
Operator
Operator
Our next question comes from Ryan Zimmerman with BTIG.
下一個問題來自 BTIG 的 Ryan Zimmerman。
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Just a couple of clarifying questions first for me. Did China actually grow because if I look at comments from Philips, United Imaging (inaudible), I mean all saw very meaningful declines. And I'm just trying to get a sense of what is happening in China and whether you guys are winning some share there or if the market is down as much as some of the others have suggested.
我先問幾個釐清性的問題。中國實際上有成長嗎?因為如果我看 Philips、United Imaging(聽不清)等公司的評論,他們都出現非常明顯的下滑。我只是想了解中國到底發生了什麼事,以及你們是否在那裡拿到一些市占,或是市場下滑幅度其實跟其他人所說的一樣大。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Ryan, we were up. So -- and we were up over where we were the previous year. Obviously, could we've done better if we didn't have the anticorruption most likely, but the team did a very nice job on it. I think when you think about many of the different businesses, we have different cycles. I would say that if you're heavily predominantly a sell and install business, meaning you take an order in the quarter and you ship in the quarter, the anticorruption early effect could have had a strong effect on you.
Ryan,我們是成長的——而且比前一年同期更高。當然,如果沒有反貪腐因素,我們是否可能做得更好?很可能是,但團隊在這方面做得非常好。我想當你看我們許多不同業務時,我們有不同的週期。我會說,如果你主要是「銷售並安裝」型的業務,也就是當季接單、當季出貨,那反貪腐的早期影響可能會對你造成很強的衝擊。
If you have more of a backlog and there's not a transaction, it's actually delivering it and shipping it for revenue. I think it could have a less effect on you. And we tend to have a larger backlog-based business. But in general, I just give a lot of credit to our China team that has done a really nice job being able to continue to execute in a market that has been a little bit unpredictable, but it's a market that we believe is -- continues to be a very important growth market into the future and all signs are that it's going to continue to grow in the future.
如果你有更多的在手訂單(backlog),而且不是靠交易本身,而是靠交付與出貨來認列營收,我認為對你的影響可能會比較小。而我們往往是較偏向以在手訂單為基礎的業務。整體而言,我要高度肯定我們中國團隊,他們在一個有點難以預測的市場中,仍能持續把執行做好。這也是我們相信未來仍會非常重要的成長市場,而且各種跡象都顯示它未來會持續成長。
But again, to translate into Q4, I would say we start Q4 with a much healthier view of China than we started Q3, but we still think there's going to be some level of effect equivalent to Q3 that will exist throughout this quarter as well.
但再說一次,換算到第四季,我會說我們在第四季開始時,對中國的看法比第三季開始時健康得多;但我們仍認為會有某種程度、與第三季相當的影響,並且在本季也會持續存在。
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Very helpful, Pete. And then, Jay, you called out the TSAs. I'm just curious kind of where you're at from a percentage standpoint in terms of rolling off TSAs from GE, what kind of impact do you expect from those in 2024?
很有幫助,Pete。接著,Jay,你提到了 TSA。我想了解一下,就從 GE 轉出的 TSA 來看,你們目前大概完成了多少比例的退場?你們預期這些在 2024 年會帶來什麼樣的影響?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. We're pleased with the progress on TSA exits. So far, we've exited approximately 130 of those, about 20 were exited early. And a lot of this relates to IT, supply chain facilities and then some other areas like HR and finance. So that whole program is on track. And as we think about 2024 and beyond, it's really important for us to get to independence to get the stability and then that allows us to unlock some incremental cost savings opportunities.
好的。我們對 TSA 退場的進度感到滿意。到目前為止,我們已退出約 130 項,其中約 20 項是提前退出。這其中很大一部分與 IT、供應鏈設施,以及其他一些領域(如人資與財務)相關。因此整個計畫都在軌道上。當我們思考 2024 年及之後,對我們來說非常重要的是達到獨立運作、取得穩定性,然後這讓我們能解鎖一些額外的成本節省機會。
For example, we have to make sure that we get our IT system stable and then we can talk about all the wonderful opportunities for optimization that we have. And so it's a real area of focus for us. And what I would say is, so far so good as it relates to becoming an independent company supporting ourselves, pleased with the progress of the 130. We have a lot that are underway right now.
例如,我們必須確保 IT 系統穩定,然後我們才能談我們所有很棒的最佳化機會。因此這是我們真正的重點聚焦領域。我想說的是,到目前為止,與成為一家獨立公司、能自我支援相關的進展都很順利;對於這 130 項的進度我們很滿意。我們現在也有很多項目正在進行中。
At the end of this year, beginning of next year, we'll make significantly more progress in terms of eliminating TSAs. And that starts to set the stage for incremental margin expansion as a stand-alone company.
在今年底、明年初,我們在消除 TSA 方面將會取得顯著更多的進展。這也開始為作為一家獨立公司帶來額外的利潤率擴張奠定舞台。
Operator
Operator
Our next question comes from Jason Bednar with Piper Sandler.
下一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - Director & Senior Research Analyst
Jason M. Bednar - Director & Senior Research Analyst
Congrats on a good quarter here. Want to follow up on some of the prior questions on orders. Sorry to beat the horse here. But I think your comments on China will come as a relief today, but can you maybe provide some of that same directional commentary for orders in your other major geographies like the U.S. or Europe for the third quarter? Was the U.S. down a little bit based on some of those project cost comments you made? And does that mean Europe was up really just trying to put the puzzle together there.
恭喜這一季表現不錯。我想延續前面一些關於訂單的問題。抱歉一直追問。但我想你們對中國的評論今天會讓大家鬆一口氣;不過你們能否也針對第三季在其他主要地區(例如美國或歐洲)的訂單,提供一些同樣方向性的評論?美國是否因為你提到的一些專案成本因素而小幅下滑?那是否代表歐洲其實是上升?我只是想把拼圖拼起來。
And then is there anything you'd call out for us to keep in mind from a comp perspective for the U.S. or Europe, like you mentioned with the China Simples program?
另外,從比較基期(comp)的角度來看,美國或歐洲有沒有什麼你希望我們留意的事項?就像你提到中國的 Simples 計畫那樣。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, I'll comment just on some of the markets, and then maybe, Jay, you can comment on any of the comp comparison pieces that are there that I missed. But again, I think on the broader market, particularly the U.S., we continue to see a solid backdrop. You heard me talk about the only kind of item that we did see was towards the end of the quarter, some of the larger deals. We're taking a little bit longer because of this point that some customers when they estimated what the total project would cost versus when they were ready to cut POs, they had a little bit higher cost. And so they had to go back through their process to get approval, which, again, sometimes could add 30, could add 60 days to the process.
好的,我先評論一些市場面向,然後也許 Jay 你可以補充我可能漏掉的任何比較基期因素。不過再說一次,就整體市場而言,特別是美國,我們持續看到穩健的背景。你也聽到我提到,我們唯一看到的項目是在季末,一些較大型的交易進度稍微拉長,原因是有些客戶在估算專案總成本時,與他們準備開 PO 時的實際成本相比,後者略高。因此他們必須回到內部流程重新取得核准;而這有時可能會讓流程多 30 天、甚至多 60 天。
And again, I don't think this is a lasting item. I think as the estimates tighten up with what the real costs are going to be that will play out. And it's not wide scale. I think there's some major cities in the United States where the cost of labor and public work, so to speak, have gone up higher. That's really the piece there.
同樣地,我不認為這會是長期因素。我認為當估算更貼近實際成本時,這個狀況就會自然消化。而且這並不是大範圍的現象。我認為在美國有一些主要城市,勞動成本以及所謂公共工程的成本上升得更高;這就是主要原因。
I do think as we talk to most customers, Western Europe and the United States, this pent-up amount of backlog of people waiting to get procedures, whether they be cardiovascular oncology, orthopedic procedures, the need for imaging, the need for other types of critical care support, whether it be monitoring or anesthesia we're still seeing as much demand or pent-up capacity -- pent-up demand that's pushing on capacity as we did at the beginning of the year.
我確實認為,當我們與多數客戶(西歐與美國)交流時,這些等待接受處置的病患積壓(backlog)——不論是心血管、腫瘤、骨科手術,對影像的需求,以及其他類型的重症照護支援需求(不論是監測或麻醉)——我們仍看到與年初一樣強勁的需求或被壓抑的需求,正在推擠產能。
Specifically for Europe, the team has been executing well on a tough macro environment. Obviously, Ukraine, Russia and then some of the conflict in the Middle East. But with regards to our customers, we're seeing some of the similar dynamics as we see in the U.S. with the approval process left taking longer but there's clearly some regional variances by country, but we continue to see the funnel of opportunities growing. And again, I think the trends are positive from a patient backlog procedure standpoint as well.
就歐洲而言,團隊在艱困的總體環境下執行得很好。顯然有烏克蘭、俄羅斯,以及中東的一些衝突。但就我們的客戶來看,我們看到一些與美國類似的動態:核准流程所需時間變長。不過各國之間確實存在區域差異;但我們仍持續看到機會漏斗在擴大。同樣地,從病患積壓與手術量的趨勢來看,我認為也是正向的。
And so again, in general, as we get out and speak with customers around the world, it's quite positive. The rest of the world, when I would say Southeast Asia and Latin America actually continues to be very bright. We're starting to see some countries in Southeast Asia that are deciding to invest pretty significant amounts to grow their capabilities. And one of the first steps they typically invest in is having high diagnostic capabilities for their folks within their region. So that's kind of the view at that point. I don't know, Jay, if anything to add.
因此再說一次,整體而言,當我們走出去與全球客戶交流時,感受是相當正向的。至於世界其他地區,我會說東南亞與拉丁美洲其實仍然非常亮眼。我們開始看到東南亞一些國家決定投入相當可觀的金額來提升其能力。而他們通常投資的第一步之一,就是在其區域內為民眾建立高水準的診斷能力。大概就是目前的看法。我不知道,Jay,你是否還要補充什麼。
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
No I think that is sufficient.
不,我認為這樣就足夠了。
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
Ryan Benjamin Zimmerman - MD & Medical Technology Analyst
And then one follow-up just seeing a disclosure in the 10-Q regarding the amendment to your employee pension plan with benefits frozen effective December of next year. I know you mentioned in your prepared remarks, Jay, can you provide some additional comments here, just what's changing with this amendment? What are the mechanics? What does it mean from a liability or cash flow perspective for GE Healthcare?
接著一個追問:我在 10-Q 中看到一項揭露,提到你們員工退休金計畫的修訂,福利將自明年 12 月起凍結生效。我知道你在事先準備的發言中提到過,Jay,你能否在這裡補充一些評論:這項修訂到底改變了什麼?運作機制是什麼?從 GE Healthcare 的負債或現金流角度來看,這代表什麼?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Sure. I would maybe take a step back and talk about we have a very active approach to managing the balance sheet. For us, this idea of having a healthy investment-grade balance sheet is really core to what we're trying to achieve. I think we've got a very good cash flowing business. And what that will allow us to do is, first, enhance the debt side of the balance sheet and then along the way, continue with business development and then also evaluate other alternatives, things like dividend, which we have in place, but also share buyback.
當然。我可能會先退一步談談:我們在管理資產負債表方面採取非常積極的作法。對我們而言,擁有健康的投資級資產負債表這個理念,是我們努力達成目標的核心。我認為我們的業務現金流非常好。而這將使我們能夠,首先,強化資產負債表的負債端,並在此過程中持續推進業務發展,同時也評估其他選項,例如股利(我們已經在發放),以及股票回購。
And so very active approach to managing the balance sheet. As it relates to the pension, we had a very large pension liability and for us, we have an active approach there as well with respect to risk reduction. We froze a remaining portion of the U.S. plan, which is effective beginning in 2025 and it doesn't really have a material impact on the size of the liability. The benefits are in 2025 and beyond, there'll be lower service costs and lower projected cash contributions everything else being equal.
因此,我們對資產負債表的管理非常積極。就退休金而言,我們有一筆非常大的退休金負債,而我們在那方面也同樣採取積極的風險降低作法。我們凍結了美國計畫中剩餘的一部分,將自 2025 年起生效,且這對負債規模並不會造成實質性的重大影響。福利在 2025 年及之後,其他條件不變的情況下,將會有較低的服務成本以及較低的預計現金提撥。
So what it really does is it sort of minimizes the range of outcomes with respect to the pension, eliminate some risk with respect to the pension versus creating a real economic windfall for us. So the savings will be in service costs over time and something that starts to show up in 2025 and beyond.
所以它真正做到的是:在退休金方面把結果的區間縮小,消除部分退休金相關風險,而不是為我們帶來真正的經濟意外之財。因此,節省將會體現在隨時間推移的服務成本上,並且會從 2025 年及之後開始逐步顯現。
Operator
Operator
Our last question comes from Suraj Kalia with Oppenheimer.
我們的最後一個問題來自 Oppenheimer 的 Suraj Kalia。
Suraj Kalia - MD & Senior Analyst
Suraj Kalia - MD & Senior Analyst
Can you hear me all right?
你們聽得到我嗎?
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
We can.
聽得到。
Suraj Kalia - MD & Senior Analyst
Suraj Kalia - MD & Senior Analyst
Congrats on the quarter. So I'll post both my questions upfront. One for Jay and one for Peter. So Jay, I understand and appreciate the commentary about a robust demand and procedure backlogs. When I look at the risk mitigation, how should we think about the various buffers that GE has vis-a-vis all the geopolitical risks right now? That's the question for you, Jay.
恭喜本季表現。所以我先把兩個問題一起提出:一個問 Jay,一個問 Peter。Jay,我理解也認同你對強勁需求與手術/處置積壓的評論。當我看風險緩解時,面對目前所有地緣政治風險,GE 相對而言有哪些不同的緩衝措施?這是給你的問題,Jay。
And Peter, forgive me, maybe I misheard it. I thought I heard you say you are looking to have a strategic collaboration to get into therapeutics in peripheral disease, maybe I misheard it, was a type 2. And it just piqued my curiosity if now you're looking at potentially entering into some therapeutic segments. Gentlemen, congrats again.
Peter,請原諒我,也許我聽錯了。我以為我聽到你說你們正在尋求策略性合作,以進入周邊疾病的治療領域,也許我聽錯了,是第二點之類的。這引起了我的好奇:你們現在是否在考慮可能進入某些治療細分領域。兩位再次恭喜。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Yes, Suraj, thanks for your question. Maybe I'll take the first one and then Jay can talk a little bit about some of the broader demand procedures now we're looking at it. What I mentioned was actually for peripheral use of Ultrasound for therapy. So I didn't mention actually going into other therapies. But we actually have had some research work that's been going on for some time on the use of peripheral ultrasound to actually help out with stimulation of different nerves, focus on the liver to actually be able to change the course of certain disease states.
是的,Suraj,謝謝你的問題。我先回答第一個,然後 Jay 可以再談談我們目前如何看更廣泛的需求與處置量。我剛才提到的其實是超音波在周邊用途上的治療應用。所以我並沒有提到要進入其他治療領域。不過,我們確實已經進行一段時間的研究工作,探討使用周邊聚焦超音波來協助刺激不同神經,並聚焦於肝臟,以便能夠改變某些疾病狀態的病程。
And so this is very early, but it's collaboration we announced with Novo Nordisk that will work together. And so this is what folks would categorize as bioelectric medicine, and again, peripheral focused ultrasound. If you're interested in it, there's actually been some articles most recently in '21, there was a great article in Nature about how the products can actually help modulate inflammation, stimulate the liver. But this is potentially an opportunity for a way of a non-pharmacological approach to actually help change disease courses as well as working in conjunction with pharmacological solutions.
因此這還非常早期,但這是我們與 Novo Nordisk 宣布的合作,將共同推進。人們通常會把這歸類為生物電醫學(bioelectric medicine),同樣是以周邊聚焦超音波為核心。如果你有興趣,其實在 2021 年左右就有一些文章,最近的一篇是在《Nature》上很棒的文章,談到這些產品如何幫助調節發炎、刺激肝臟。但這可能提供一個機會:以非藥物方式來幫助改變疾病病程,同時也可以與藥物解決方案搭配使用。
So this is obviously a longer-term investment. But it's something actually that is actually funded in the near term with our partner and we'll work jointly on this. But this is a pretty exciting opportunity to leverage what we know and partner up with the world-class pharmaceutical company. Jay?
所以這顯然是一項較長期的投資。但在短期內,這項計畫實際上由我們的合作夥伴提供資金,我們將共同推進。不過,這是一個相當令人振奮的機會,能夠運用我們所掌握的能力,並與世界級製藥公司合作。Jay?
James K. Saccaro - VP & CFO
James K. Saccaro - VP & CFO
Yes, sure. As it relates to your first question, it's interesting because if you think about 2023, we've had a highly volatile macroeconomic backdrop. And yet, the sales for our company have been quite resilient and ahead of our original expectations, we originally expected 5% to 7%. We now expect 6% to 8% and again confronted with a very volatile macro backdrop that we've discussed today, and we've discussed on previous calls.
好的,當然。就你的第一個問題而言,這很有意思,因為如果你回想 2023 年,我們面對的是高度波動的總體經濟背景。然而,我們公司的銷售表現相當具韌性,且優於我們原先的預期;我們原本預期是 5% 到 7%,現在我們預期是 6% 到 8%。而這是在我們今天以及先前電話會議中討論過的、非常波動的宏觀背景下達成的。
What it really comes down to is a few things that buffer us. Number one is the backlog that we've discussed. At the end of the day, when customers put in orders, they typically have a very acute need that they would like satisfied with products that we have. And so that backlog of $18-plus billion backlog has served us incredibly well.
歸根結底,能夠為我們提供緩衝的有幾點。第一是我們討論過的訂單積壓。最終,當客戶下單時,通常是因為他們有非常迫切的需求,希望用我們的產品來滿足。因此,超過 180 億美元的訂單積壓對我們幫助非常大。
The second thing that we have in place is the fact that we have nearly half of our business or so is recurring revenue. And so things like PDx, things like our Service business, these are all things that we can count on reliably, again, even despite a volatile macro backdrop.
第二點是,我們大約有接近一半的業務屬於經常性收入。因此像 PDx、像我們的服務業務,這些都是我們可以相對可靠地依賴的收入來源,即使在波動的宏觀背景下也是如此。
The final thing that I would say is, as we have this lean operating model in place, it's really about efficiency and managing costs effectively such that you have a third layer of protection against a volatile macro situation. So overall, I think the business has fared quite well and the setup is good for 2024 as we look forward. I will leave it at that and maybe turn it over to Pete for some final comments.
最後我想說的是,隨著我們建立精實的營運模式,重點在於效率以及有效管理成本,從而在面對波動的宏觀情勢時提供第三層保護。總體而言,我認為業務表現相當不錯,且展望 2024 年的基礎也很好。我就先說到這裡,接著交給 Pete 做一些最後的補充。
Peter J. Arduini - President, CEO & Director
Peter J. Arduini - President, CEO & Director
Great, Jay. So look, well, thanks, everyone, for joining us today. It's been 10 months in spend. It's amazing how fast time flies. We're successfully worked through a number of the macro challenges, some we just talked about, and our teams really delivered well on its commitments. We're looking forward to closing out the year and maintaining strong momentum as we approach 2024. We hope to see many of you and some of you, if not, soon at the Radiological Society of North America in Chicago, one of our biggest congresses at the end of November or one at the upcoming investor meetings we'll participate in. That ends the call. Thank you very much.
很好,Jay。那麼,謝謝各位今天加入我們。分拆後已經 10 個月了,時間過得真快。我們已成功克服多項宏觀挑戰,其中一些我們剛才也談到了,而我們的團隊也確實很好地履行了承諾。我們期待順利完成今年,並在邁向 2024 年之際維持強勁動能。我們希望在 11 月底於芝加哥舉行的北美放射學會(Radiological Society of North America)——我們最大的會議之一——能見到各位中的許多人;或者在我們將參與的後續投資人會議上與各位見面。電話會議到此結束。非常感謝。
Operator
Operator
Thank you for your participation. You may now disconnect. Everyone, have a great day.
感謝各位的參與。您現在可以掛線。各位,祝您有美好的一天。